Tempest Therapeutics’ (TPST) “Neutral” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report published on Thursday morning, Marketbeat reports. They currently have a $16.00 target price on the stock. Separately, Scotiabank reissued a “sector perform” rating and set a $9.00 price objective (up previously from $7.00) on shares of Tempest […]
HC Wainwright reaffirmed their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report published on Thursday morning, Marketbeat reports. They currently have a $16.00 target price on the stock. Separately, Scotiabank reissued a “sector perform” rating and set a $9.00 price objective (up previously from $7.00) on shares of Tempest […]
